statistiche ricercatore

MARTIGNONI, EMILIA SILVANA

Distribuzione geografica

Continente	#
NA - Nord America	5.807
EU - Europa	3.458
AS - Asia	1.483
SA - Sud America	146
AF - Africa	7
OC - Oceania	7
Continente sconosciuto - Info sul continente non disponibili	6
Totale	10.914

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	5.778
IT - Italia	1.724
UA - Ucraina	617
SG - Singapore	578
SE - Svezia	286
TR - Turchia	244
VN - Vietnam	205
IE - Irlanda	193
HK - Hong Kong	192
CN - Cina	175
FI - Finlandia	172
GB - Regno Unito	160
BR - Brasile	127
DE - Germania	121
RU - Federazione Russa	84
IN - India	33
FR - Francia	32
BE - Belgio	21
CA - Canada	19
JP - Giappone	15
BD - Bangladesh	12
AT - Austria	8
NL - Olanda	8
ES - Italia	7
EU - Europa	6
AR - Argentina	5
PL - Polonia	5
BG - Bulgaria	4
ID - Indonesia	4
MX - Messico	4
NZ - Nuova Zelanda	4
AU - Australia	3
CL - Cile	3
CO - Colombia	3
IQ - Iraq	3
LT - Lituania	3
TH - Thailandia	3
VE - Venezuela	3
ZA - Sudafrica	3
AE - Emirati Arabi Uniti	2
BB - Barbados	2
DK - Danimarca	2
EC - Ecuador	2
HR - Croazia	2
IL - Israele	2
JO - Giordania	2
MA - Marocco	2
MY - Malesia	2
PK - Pakistan	2
PY - Paraguay	2
SA - Arabia Saudita	2
CH - Svizzera	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
EG - Egitto	1
GL - Groenlandia	1
GR - Grecia	1
HN - Honduras	1
HU - Ungheria	1
IM - Isola di Man	1
KG - Kirghizistan	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LK - Sri Lanka	1
LU - Lussemburgo	1
MK - Macedonia	1
NO - Norvegia	1
PE - Perù	1
QA - Qatar	1
RO - Romania	1
SV - El Salvador	1
TN - Tunisia	1
UZ - Uzbekistan	1
Totale	10.914

Salva come PNG Salva come JPEG

Città	#
Milan	1.301
Fairfield	795
Chandler	587
Jacksonville	463
Woodbridge	442
Ashburn	388
Seattle	371
Houston	324
Singapore	320
Wilmington	302
Ann Arbor	253
Cambridge	250
Dublin	192
Hong Kong	191
Dallas	163
Princeton	154
Izmir	145
Nyköping	144
Boardman	104
Dong Ket	88
Chicago	87
San Mateo	77
Como	70
Rome	69
The Dalles	63
Dearborn	60
Beijing	44
San Diego	43
Ogden	33
Philadelphia	30
Los Angeles	24
Norwalk	20
Brussels	19
Santa Clara	19
Düsseldorf	18
Pune	17
São Paulo	16
Hanoi	15
Ho Chi Minh City	15
Munich	14
Edinburgh	13
New York	13
London	12
Tokyo	12
Turku	12
Verona	11
Atlanta	10
Kunming	9
Nanjing	8
San Francisco	8
Hefei	7
Nanchang	7
Auburn Hills	6
Brasília	6
Helsinki	6
Montreal	6
Amsterdam	5
Brooklyn	5
Toronto	5
Dhaka	4
Fuzhou	4
Guangzhou	4
Jinan	4
Rio de Janeiro	4
Stockholm	4
Belo Horizonte	3
Boston	3
Charlotte	3
Chengdu	3
Chongqing	3
Columbus	3
Council Bluffs	3
Curitiba	3
Fayetteville	3
Frankfurt am Main	3
Johannesburg	3
Kocaeli	3
Madrid	3
Miami	3
Nuremberg	3
Porto Alegre	3
Redwood City	3
Sofia	3
Vienna	3
Washington	3
Amman	2
Annapolis	2
Auckland	2
Bangkok	2
Barra Mansa	2
Bauru	2
Bogotá	2
Bologna	2
Brisbane	2
Campinas	2
Carapicuíba	2
Casablanca	2
Chennai	2
Copenhagen	2
Da Nang	2
Totale	8.005

Salva come PNG Salva come JPEG

Nome	#
Calcium homeostasis is dysregulated in parkinsonian patients with l-DOPA-induced dyskinesias	215
5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms	196
Changes of opioid modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual syndrome.	186
Disordered pupil reactivity in Parkinson's disease.	176
CARDIOVASCULAR AUTONOMIC MODULATION AND ACTIVITY OF CAROTID BARORECEPTORS AT ALTITUDE.	176
Changes of neuroendocrine axes in patients with menstrual migraine.	173
Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type.	170
Autonomic regulation of heart rate and peripheral circulation: comparison of high altitude and sea level residents.	168
Stimulation of corticotrophin-releasing hormone release by the obese (ob) gene product, leptin, from hypothalamic explants.	167
BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease	166
A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.	165
The brain as a target for adrenocortical steroids: cognitive implications.	161
Changes in nociceptive flexion reflex threshold across the menstrual cycle in healthy women.	161
The association of menstrual migraine with the premenstrual syndrome.	161
"Off" painful dystonia in Parkinson's disease treated with botulinum toxin.	158
Combined response of plasma and platelet catecholamines to different types of short-term stress.	158
Neuroendocrine changes in luteal function in patients with premenstrual syndrome.	158
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study.The influence of age.	157
Psychometric properties of the Unified Parkinson's Disease Rating Scale and of the Short Parkinson's Evaluation Scale.	156
High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.	156
An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics.	154
Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women.	153
Is seborrhea a sign of autonomic impairment in Parkinson's disease?	153
Platelet catecholamines in cluster headache.	152
Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection.	151
Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.	151
Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson's disease.	151
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.	151
Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans.	150
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.	150
Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.	149
Functional changes of the basal ganglia circuitry in Parkinson's disease.	149
Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.	149
Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.	148
Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.	148
The role of language areas in motor control dysfunction in Parkinson's disease.	147
Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo.	146
Nocturnal sleep in multisystem atrophy with autonomic failure: polygraphic findings in ten patients.	146
Non-hormonal therapy of premenstrual syndrome.	145
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson’s disease. The effect of dopaminergic treatment	144
Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psychosom Med. 2000 May-Jun;62(3):386-93.	143
Changes in motoneuron excitability of masseter muscle following exteroceptive stimuli in Parkinson's disease.	142
Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus.	142
Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study.	140
Interobserver reliability between neurologists in training of Parkinson's disease rating scales. A multicenter study.	140
Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients	140
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease	140
Sleep attacks in Parkinson's disease: a clinical and polysomnographic study.	138
Motor complications of Parkinson's disease.	137
LISURIDE PLUS SELEGILINE IN THE TREATMENT OF EARLY PARKINSON'S DISEASE.	136
Parkinson's disease and reproductive life events.	136
Premenstrual dysphoric disorder and eating disorders.	135
The influence of gender in the evaluation of platelet and plasma catecholamines.	134
Medical healthcare use in Parkinson’s disease: survey in a cohort of ambulatory patients in Italy.	133
Pergolide compared with bromocriptine in Parkinson's disease: a multicenter,crossover, controlled study.	131
Expression polymorphism of the blood-brain barrier component P-glycoprotein(MDR1) in relation to Parkinson's disease.	131
Hashimoto's thyroiditis in association with Tolosa Hunt syndrome: a case report.	130
Active music therapy and Parkinson's disease: methods.	129
Electrophysiological study on jaw-opening reflex recorded from digastric muscle in Parkinson's disease and primary cranial dystonias.	128
The autonomic nervous system and hypoxia: mountain medicine.	125
Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation.	125
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.	124
CARDIOPRESSOR EFFECTS OF SHORT-TERM TREATMENT WITH CABERGOLINE IN L-DOPA STABLE RESPONDER PARKINSONIAN PATIENTS: RELEVANCE OF POSTPRANDIAL HYPOTENSION.	120
Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol. 2000 Sep;62(1):63-88.	119
ALTITUDE, EXERCISE, AND MOUNTAIN MEDICINE: LESSONS FROM THE FIELD.	118
Autonomic disorders in Parkinson's disease.	114
Terguride in stable Parkinson's disease.	113
The effects of physical exercise at high altitude on adrenocortical function in humans.	111
LISURIDE AND BROMOCRYPTINE IN L-DOPA STABLE-RESPONDER PARKINSONIAN PATIENTS: A COMPARATIVE, DOUBLE-BLIND EVALUATION OF CARDIOPRESSOR AND NEUROCHEMICAL EFFECTS.	110
Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.	108
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease	106
Reproductive life milestones in women with Parkinson's disease.	105
Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.	102
Further characterization of autonomic involvement in multiple system atrophy: a pupillometric study.	95
COMT inhibition and safety.	95
Parkinson's Disease Comorbidity Study Group. Comorbid disorders and hospitalisation in Parkinson's disease: a prospective study.	95
Evidence of alpha-N-acetyl beta-endorphin in human cerebrospinal fluid.	88
Totale	10.929

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	37.754
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	37.754

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	805	0	0	0	0	0	145	49	101	186	49	109	166
2021/2022	824	93	66	80	112	12	46	28	38	30	116	62	141
2022/2023	1.405	104	89	219	128	93	302	0	172	165	46	59	28
2023/2024	1.987	342	358	334	355	361	88	6	69	47	14	2	11
2024/2025	1.019	2	31	245	31	13	67	11	68	130	61	79	281
2025/2026	878	123	100	111	218	287	39	0	0	0	0	0	0
Totale													10.929